Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

The Boardroom

- PMLiVE

ViiV maintains top spot in reputation survey

But former top-ranked Gilead slides down in PatientView poll of patient groups

Gilead Sciences

Gilead and Achillion see 100% success rate in hep C trial

New combination treatment aims to compete in a rapidly evolving market for the disease

Roche Basel Switzerland

Fresh approval for Roche’s Lucentis as competition heats up

Approved for more diabetes-related eye complications

Roche - Basel

Roche’s PD-1 wins second FDA ‘breakthrough’ status

Will accelerate review of MPDL3280A in lung cancer

Roche Basel Switzerland

Roche’s newer breast cancer drugs gain traction

Perjeta and Kadcyla boost 2014 revenues

- PMLiVE

Former Roche CEO joins BIAL board

Franz Humer to advise Portuguese pharma company

Gilead Sciences

Gilead cuts hepatitis C drug prices in Germany

Discount on Sovaldi and Harvoni follows similar agreement in France

Roche Basel Switzerland

Roche buys rare disease firm Trophos in €470m deal

Will take control of olesoxime for spinal muscular atrophy

Roche Basel Switzerland

Roche pays $1bn-plus for stake in genomics specialist

Shares in Foundation Medicine Inc doubled following the announcement

- PMLiVE

Sovaldi dropped by Express Scripts in favour of Viekira Pak

Pharmacy benefits organisation ramps up US pricing pressure on Gilead

- PMLiVE

Double trial disappointment for Roche

Discontinues Alzheimer’s programme and finds Kadcyla no better than Herceptin in certain breast cancer

Roche - Basel

Roche leads pharma R&D spend for 2013

Top 30 pharma companies spent a total of $112bn on research

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links